38 results about "Displacement chromatography" patented technology

The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα is detrimental, are also provided.

Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein.

Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein.

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables one to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.

There are only two ways to increase the amount of sample that can be purified by preparative reversed phase high performance liquid chromatography (Prep-RP-HPLC) in a single run in spite of recent advances in the production of reversed phase derivatized silica stationary supports: (1) the traditional approach is to use a bigger column (greater amount of stationary phase); and (2) use displacement chromatography which (while labor intensive to develop) uses the stationary phase more effectively. This invention describes a unique Prep-RP-HPLC technique that uses a C-18 / C-8 derivatized silica coated with a surfactant such as Triton X-100 to result in 7 to 10 fold increase in sample loading (of the crude mixture of organic compounds including synthetic crude peptides) in contrast to the conventional Prep-RP-HPLC technique. This increase in sample loading capacity and output is due to the additional surrogate stationary phase characteristic of the C-18 / C8 adsorbed (bound) surfactant. The surfactant is bound to the C-18 / C-8 chains of the stationary phase via Van der Waals forces (hydrophobic interactions) and ionic interactions with the residual silanols of the stationary phase.

A method of separating an organic compound from a mixture by reversed-phase displacement chromatography comprising providing a hydrophobic stationary phase; applying to the hydrophobic stationary phase a mixture comprising the organic compound to be separated; by applying to the hydrophobic stationary phase a non-surface active hydrophobic an aqueous composition of a neutral zwitterion displacer molecule and optionally an organic solvent to displace the organic compound from the hydrophobic stationary phase; and collecting a plurality of fractions containing the separated organic compound eluting from the hydrophobic stationary phase; wherein The non-surface active hydrophobic neutral zwitterion displacer molecule comprises a hydrophobic zwitterion having the general formula [CM-R*-CM'] as defined in the specification.

The invention discloses a displacement chromatography hydrogen isotope separation device which comprises a rack as well as a cooling part, a separation column, an air supply part, an air collection part, a lifting part and a driving part. By adopting the displacement chromatography hydrogen isotope separation device disclosed by the invention, different adsorption functions that hydrogen and hydrogen isotope are replaced and separated by using a separation material can be achieved, the lifting part is driven by the driving part to precisely control the lifting position of the separation column, and then the separation column can be descended or lifted off the cooling part, so that adsorption or desorption of hydrogen isotope by the separation material under different temperature conditions can be achieved, a high retention rate of deuterium-tritium isotope in the separation material can be ensured, and a deuterium-tritium isotope gas obtained through final separation and selection is relatively high in purity; compared with the prior art, the device needs no parts for introducing deuterium or separating deuterium, meanwhile deuterium and tritium do not need to be replaced by introducing hydrogen after the separation material is in saturation adsorption of hydrogen, and in addition, the device is simple in structure, low in energy consumption rate, simple in process and low in cost.